|
1
|
Vredenburgh JJ, Desjardins A, Reardon DA
and Friedman HS: Experience with irinotecan for the treatment of
malignant glioma. Neuro Oncol. 11:80–91. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Xie Q, Mittal S and Berens ME: Targeting
adaptive glioblastoma: An overview of proliferation and invasion.
Neuro Oncol. 16:1575–1584. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Preusser M, Haberler C and Hainfellner JA:
Malignant glioma: Neuropathology and neurobiology. Wien Med
Wochenschr. 156:332–337. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Vigneswaran K, Neill S and Hadjipanayis
CG: Beyond the World Health Organization grading of infiltrating
gliomas: Advances in the molecular genetics of glioma
classification. Ann Transl Med. 3:952015.PubMed/NCBI
|
|
5
|
Cohen AL and Colman H: Glioma biology and
molecular markers. Cancer Treat Res. 163:15–30. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Stupp R, Mason WP, van den Bent MJ, Weller
M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn
U, et al: European Organisation for Research and Treatment of
Cancer Brain Tumor and Radiotherapy Groups; National Cancer
Institute of Canada Clinical Trials Group: Radiotherapy plus
concomitant and adjuvant temozolomide for glioblastoma. N Engl J
Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Davis FG and McCarthy BJ: Current
epidemiological trends and surveillance issues in brain tumors.
Expert Rev Anticancer Ther. 1:395–401. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Makeyev EV and Maniatis T: Multilevel
regulation of gene expression by microRNAs. Science. 319:1789–1790.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bartels CL and Tsongalis GJ: MicroRNAs:
Novel biomarkers for human cancer. Clin Chem. 55:623–631. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Esquela-Kerscher A and Slack FJ: Oncomirs
- microRNAs with a role in cancer. Nat Rev Cancer. 6:259–269. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu Z, Dou C, Yao B, Xu M, Ding L, Wang Y,
Jia Y, Li Q, Zhang H, Tu K, et al: Methylation-mediated repression
of microRNA-129-2 suppresses cell aggressiveness by inhibiting high
mobility group box 1 in human hepatocellular carcinoma. Oncotarget.
7:36909–36923. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wu J, Cui H, Zhu Z and Wang L:
MicroRNA-200b-3p suppresses epithelial-mesenchymal transition and
inhibits tumor growth of glioma through down-regulation of ERK5.
Biochem Biophys Res Commun. 478:1158–1164. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Deng B, Zhang Y, Zhang S, Wen F, Miao Y
and Guo K: MicroRNA-142-3p inhibits cell proliferation and invasion
of cervical cancer cells by targeting FZD7. Tumour Biol.
36:8065–8073. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Malzkorn B, Wolter M, Liesenberg F,
Grzendowski M, Stühler K, Meyer HE and Reifenberger G:
Identification and functional characterization of microRNAs
involved in the malignant progression of gliomas. Brain Pathol.
20:539–550. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cao XC, Yu Y, Hou LK, Sun XH, Ge J, Zhang
B and Wang X: miR-142-3p inhibits cancer cell proliferation by
targeting CDC25C. Cell Prolif. 49:58–68. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pan D, Du Y, Ren Z, Chen Y, Li X, Wang J
and Hu B: Radiation induces premature chromatid separation via the
miR-142-3p/Bod1 pathway in carcinoma cells. Oncotarget.
7:60432–60445. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ma Z, Liu T, Huang W, Liu H, Zhang HM, Li
Q, Chen Z and Guo AY: MicroRNA regulatory pathway analysis
identifies miR-142-5p as a negative regulator of TGF-β pathway via
targeting SMAD3. Oncotarget. 7:71504–71513. 2016.PubMed/NCBI
|
|
18
|
Zheng Z, Ding M, Ni J, Song D, Huang J and
Wang J: miR-142 acts as a tumor suppressor in osteosarcoma cell
lines by targeting Rac1. Oncol Rep. 33:1291–1299. 2015.PubMed/NCBI
|
|
19
|
Su YH, Zhou Z, Yang KP, Wang XG, Zhu Y and
Fa XE: MIR-142-5p and miR-9 may be involved in squamous lung cancer
by regulating cell cycle related genes. Eur Rev Med Pharmacol Sci.
17:3213–3220. 2013.PubMed/NCBI
|
|
20
|
Yin Y, Song M, Gu B, Qi X, Hu Y, Feng Y,
Liu H, Zhou L, Bian Z, Zhang J, et al: Systematic analysis of key
miRNAs and related signaling pathways in colorectal tumorigenesis.
Gene. 578:177–184. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shen WW, Zeng Z, Zhu WX and Fu GH:
MiR-142-3p functions as a tumor suppressor by targeting CD133,
ABCG2, and Lgr5 in colon cancer cells. J Mol Med. 91:989–1000.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Xu G, Wang J, Jia Y, Shen F, Han W and
Kang Y: MiR-142-3p functions as a potential tumor suppressor in
human osteosarcoma by targeting HMGA1. Cell Physiol Biochem.
33:1329–1339. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kaduthanam S, Gade S, Meister M, Brase JC,
Johannes M, Dienemann H, Warth A, Schnabel PA, Herth FJ, Sültmann
H, et al: Serum miR-142-3p is associated with early relapse in
operable lung adenocarcinoma patients. Lung Cancer. 80:223–227.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Qi X, Li J, Zhou C, Lv C and Tian M:
MiR-142-3p suppresses SOCS6 expression and promotes cell
proliferation in nasopharyngeal carcinoma. Cell Physiol Biochem.
36:1743–1752. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pelloni M, Coltrinari G, Paoli D, Pallotti
F, Lombardo F, Lenzi A and Gandini L: Differential expression of
miRNAs in the seminal plasma and serum of testicular cancer
patients. Endocrine. Oct 28–2016.(Epub ahead of print). https://doi.org/10.1007/s12020-016-1150-z
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Summerer I, Unger K, Braselmann H,
Schuettrumpf L, Maihoefer C, Baumeister P, Kirchner T, Niyazi M,
Sage E, Specht HM, et al: Circulating microRNAs as prognostic
therapy biomarkers in head and neck cancer patients. Br J Cancer.
113:76–82. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lin RJ, Xiao DW, Liao LD, Chen T, Xie ZF,
Huang WZ, Wang WS, Jiang TF, Wu BL, Li EM, et al: MiR-142-3p as a
potential prognostic biomarker for esophageal squamous cell
carcinoma. J Surg Oncol. 105:175–182. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li Y, Chen D, Jin LU, Liu J, Li Y, Su Z,
Qi Z, Shi M, Jiang Z, Yang S, et al: Oncogenic microRNA-142-3p is
associated with cellular migration, proliferation and apoptosis in
renal cell carcinoma. Oncol Lett. 11:1235–1241. 2016.PubMed/NCBI
|
|
29
|
Isobe T, Hisamori S, Hogan DJ, Zabala M,
Hendrickson DG, Dalerba P, Cai S1, Scheeren F, Kuo AH1, Sikandar
SS, et al: miR-142 regulates the tumorigenicity of human breast
cancer stem cells through the canonical WNT signaling pathway.
Elife. 3:doi: 10.7554/eLife.01977. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Schwickert A, Weghake E, Brüggemann K,
Engbers A, Brinkmann BF, Kemper B, Seggewiß J, Stock C, Ebnet K,
Kiesel L, et al: microRNA miR-142-3p inhibits breast cancer cell
invasiveness by synchronous targeting of WASL, integrin alpha V,
and additional cytoskeletal elements. PLoS One. 10:e01439932015.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Xiao P and Liu WL: MiR-142-3p functions as
a potential tumor suppressor directly targeting HMGB1 in
non-small-cell lung carcinoma. Int J Clin Exp Pathol.
8:10800–10807. 2015.PubMed/NCBI
|
|
32
|
Wu L, Cai C, Wang X, Liu M, Li X and Tang
H: MicroRNA-142-3p, a new regulator of RAC1, suppresses the
migration and invasion of hepatocellular carcinoma cells. FEBS
Lett. 585:1322–1330. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yoon CH, Hyun KH, Kim RK, Lee H, Lim EJ,
Chung HY, An S, Park MJ, Suh Y, Kim MJ, et al: The small GTPase
Rac1 is involved in the maintenance of stemness and malignancies in
glioma stem-like cells. FEBS Lett. 585:2331–2338. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhong J, Bach CT, Shum MS and O'Neill GM:
NEDD9 regulates 3D migratory activity independent of the Rac1
morphology switch in glioma and neuroblastoma. Mol Cancer Res.
12:264–273. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Man J, Shoemake J, Zhou W, Fang X, Wu Q,
Rizzo A, Prayson R, Bao S, Rich JN and Yu JS: Sema3C promotes the
survival and tumorigenicity of glioma stem cells through Rac1
activation. Cell Rep. 9:1812–1826. 2014. View Article : Google Scholar : PubMed/NCBI
|
